Figure 1. Effects of different treatments on modulation of tumor xenograft volume and size.
The mice were subcutaneously injected with NSCLC A549 cells and when tumor xenografts reached 5–6 mm3, the mice received different treatments (n = 8 mice/group) for up to 6 weeks. (A) Comparison of single drug treatment with the negative control. During the treatment, tumor xenograft volumes were measured twice a week for 3 weeks. (B) Comparison of a regular icotinib dose plus or sequential docetaxel treatment with the negative control. C. Comparison of a high icotinib dose plus or sequential docetaxel treatment with the negative control. Control, negative control; DTX, docetaxel; IcoR, a regular icotinib dose; IcoH, a high icotinib dose; IcoH-D, a high icotinib dose and sequential docetaxel for 3 weeks; IcoR-D, a regular icotinib dose and sequential docetaxel for 3 weeks; IcoH+D, a high icotinib dose plus docetaxel for 3 weeks; IcoR+D, a regular icotinib dose plus docetaxel for 3 weeks; D-IcoR, docetaxel and sequential regular icotinib dose for 3 weeks; D-IcoH, docetaxel and sequential high icotinib dose for 3 weeks.